Market Place
Sourcing Support
Equillium Announces Interim EQUATOR GVHD Enrollment Achieved
14 May 2024 //
BUSINESSWIRE
Equillium Announces Positive Data from the Ph 1b EQUALISE study
01 Apr 2024 //
BUSINESSWIRE
Equillium delivers new lupus data to Ono`s doorstep
01 Apr 2024 //
FIERCE BIOTECH
Biocon starts clinical study to evaluate efficacy of Itolizumab
15 Dec 2022 //
ECONOMIC TIMES
Equillium and Ono Pharmaceutical Announce Agreement for Itolizumab
06 Dec 2022 //
BUSINESSWIRE
Equillium Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
Equillium Initiates Phase 3 EQUATOR Study of Itolizumab in GvHD
04 Mar 2022 //
BUSINESSWIRE
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
09 Feb 2022 //
BUSINESSWIRE
Equillium Announces Data from Phase 1b EQUIP Study in Uncontrolled Asthma
04 Jan 2022 //
BUSINESSWIRE
Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis
24 Dec 2021 //
EXPRESSPHARMA
Biocon Biologics initiates Itolizumab study in India post DCGI approval
24 Dec 2021 //
ECONOMICTIMES
Equillium Reports Q3 2021 Financial Results, Provides Clinical Updates
10 Nov 2021 //
BUSINESSWIRE
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus
02 Nov 2021 //
BUSINESSWIRE
Equillium to Present at the H.C. Wainwright Investment Conference
08 Sep 2021 //
BUSINESSWIRE
Equillium Reports Second Quarter 2021 Financial Results and Development Update
10 Aug 2021 //
BUSINESSWIRE
How are pharma companies dealing with challenges posed by Covid-19?
21 Apr 2021 //
PRESS RELEASE
Equillium Announces Positive Interim Data of Itolizumab in the First-line
06 Nov 2020 //
GLOBENEWSWIRE
Maharashtra FDA assures CDSCO of adequate stock of essential COVID-19 drugs
05 Oct 2020 //
PHARMABIZ
Sales of Biocon`s itolizumab surge as phase-4 clinical trials begin
05 Oct 2020 //
BUSINESS STANDARD
Equillium Presented New Data & Insights on the CD6-ALCAM Pathway
17 Sep 2020 //
BIOSPACE
Equillium Announces Advancement of Itolizumab
15 Sep 2020 //
GLOBENEWSWIRE
Experts concerned over exclusion of Itolizumab FAQs issued by health ministry
04 Sep 2020 //
PHARMABIZ
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
10 Aug 2020 //
GLOBENEWSWIRE
Health ministry decides against including Itolizumab in clinical management protocols for COVID-19
27 Jul 2020 //
SCIENCEDAILY
Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw
24 Jul 2020 //
BUSINESS-STANDARD
India clears a psoriasis drug for COVID-19, and a tiny US biotech`s shares soar
13 Jul 2020 //
BIOPHARMADIVE
Biocon readies for phase IV studies with itolizumab for COVID-19, set to ramp up
13 Jul 2020 //
PHARMABIZ
DCGI approves Itolizumab for restricted emergency use in COVID-19 treatment
11 Jul 2020 //
EXPRESSPHARMA
Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients
10 Jul 2020 //
MONEYCONTROL
Biocon says use of Itolizumab in COVID-19 treatment encouraging
15 May 2020 //
ECONOMICTIMES
Biocon extends licensing pact with Equillium for itolizumab
13 Dec 2019 //
ECONOMIC TIMES
Equillium Announces Initiation of EQUIP Phase 1b Clinical Trial of Itolizumab
10 Jul 2019 //
GLOBE NEWSWIRE
